Michelson Diagnostics targets US market for skin cancer imaging products

5 August 2011

Michelson Diagnostics has announced plans to expand availability of its revolutionary products for skin cancer imaging in the United States with the formation of a US subsidiary.

The company has recruited Karen Miller Gillis as VP Sales & Marketing / General Manager of its new US subsidiary Michelson Diagnostics Inc., which is based in Massachusetts. She brings 16 years’ sales and marketing experience in the medtech industry.

“Karen’s background in sales and marketing of pay-per-use billing will be hugely useful as we roll out our commercial expansion in the USA”, said Michelson Diagnostics Ltd CEO Jon Holmes. “Her commitment, drive and expert communication skills were evident as soon as I met her, and I look forward to working with Karen in this exciting period for the company.” he added.

“We believe that Michelson Diagnostics’ product, the VivoSight OCT scanner, will provide dermatologists with new and very useful information about what is happening below the surface of the skin of their patients who are receiving treatment for non-melanoma skin cancer.” said Karen. “Patients who suffer from non-melanoma skin cancer will also benefit from the non-invasive scan which allows their dermatologist to check at prescribed intervals to ensure that treatment is progressing as expected, and in some cases potentially avoid the biopsy procedure and related waiting time.”

The VivoSight OCT scanner has received FDA clearance for clinical use in the United States, and is currently being trialed by leading skin cancer specialists at their clinics.

Source: Michelson Diagnostics